One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Hims & Hers Health, Inc. (HIMS) shares rallied 27.7% in the last trading session to close at $59.18. This move can be attributable to notable volume with a higher number of shares being traded than in ...

We recently published a list of 10 Firms Post Double-Digit Gains on Thursday. In this article, we are going to take a look at ...

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

A direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention the side effects of the drugs.

Hims & Hers Health Inc (NYSE:HIMS) is one of the best stocks on the New York Stock Exchange (NYSE), up 21.3% at $56.22 at last glance, earlier hitting a fresh record high of $56.71, after the ...

Viewers of the Super Bowl may have seen an ad from one of the largest compounders in the United States, Hims & Hers, ...